Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Clinical trial NCT03736967 · TERMINATED
Trial details
- NCT number
- NCT03736967
- Sponsor
- Regeneron Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-12
- Primary completion
- 2020-03-13
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.